EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Transforming Acute Myeloid Leukemia Care through Precision Medicine: Integrating Genomic Profiling, Measurable Residual Disease, and Targeted Therapies

Rafal Al-Shibly, Maria Benkhadra, Mohamed A Yassin

Oncology · 30.03.2026 · 1-12

DOI: 10.1159/000551702 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology, online erschienen am 30.03.2026. Verfasst von Rafal Al-Shibly und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education, Internal Medicine Residency Program, Hamad Medical Corporation, Doha, Qatar, RAlshebly@hamad.qa. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Precision Medicine, Molecular Targeted Therapy. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Acute myeloid leukemia (AML) is a biologically heterogeneous and clinically aggressive hematologic malignancy, with outcomes that remain poor for many older adults and patients with adverse-risk disease. Advances in cytogenetics and next-generation sequencing have identified actionable molecular lesions, including FLT3, IDH1/2, and NPM1, enabling biomarker-driven risk stratification and more individualized therapeutic approaches. Summary: Since 2017, multiple targeted therapies and antibody-drug conjugates, often combined with intensive chemotherapy or hypomethylating agents, have improved remission rates in molecularly defined AML subsets. Measurable residual disease (MRD) assessment using multiparameter flow cytometry and molecular assays is increasingly incorporated into post-remission evaluation to inform decisions regarding transplantation and maintenance therapy. However, its clinical utility remains limited by assay variability, interference from clonal hematopoiesis, and the lack of robust evidence supporting MRD-directed interventions. This narrative review synthesizes the evolving genomic landscape of AML, current guideline-endorsed targeted therapies, and emerging investigational strategies, while outlining a practical framework that integrates genomic profiling, MRD-informed decision-making, and algorithmic treatment pathways. Key Messages: Precision medicine is reshaping AML management through genomic classification, targeted therapies, and evolving MRD applications. A practical treatment framework that incorporates molecular profiling and post-remission risk assessment may improve clinical decision-making, although real-world barriers to implementation and issues of equity remain important challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcutePrecision MedicineMolecular Targeted TherapyHumansNeoplasm, ResidualNucleophosminGenomicsBiomarkers, Tumor

Stichwörter der Autor:innen

Acute myeloid leukemiaGenomic profilingMeasurable residual diseasePrecision medicineTargeted therapy

Substanzen

NucleophosminNPM1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Education, Internal Medicine Residency Program, Hamad Medical Corporation, Doha, Qatar, RAlshebly@hamad.qa.
  • Department of Pharmacy, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Qatar University, College of Medicine, Doha, Qatar.

Zitieren

APA

Al-Shibly, R., Benkhadra, M., & Yassin, M. A. (2026). Transforming Acute Myeloid Leukemia Care through Precision Medicine: Integrating Genomic Profiling, Measurable Residual Disease, and Targeted Therapies. Oncology, 1-12. https://doi.org/10.1159/000551702

Vancouver

Al-Shibly R, Benkhadra M, Yassin MA. Transforming Acute Myeloid Leukemia Care through Precision Medicine: Integrating Genomic Profiling, Measurable Residual Disease, and Targeted Therapies. Oncology. 2026:1-12. doi:10.1159/000551702

BibTeX
@article{AlShibly2026,
  author = {Al-Shibly, Rafal and Benkhadra, Maria and Yassin, Mohamed A},
  title = {Transforming Acute Myeloid Leukemia Care through Precision Medicine: Integrating Genomic Profiling, Measurable Residual Disease, and Targeted Therapies},
  journal = {Oncology},
  year = {2026},
  pages = {1--12},
  doi = {10.1159/000551702}
}
Kostenlos starten →